95 related articles for article (PubMed ID: 10087416)
1. Effect of treatment with GnRH agonists on new markers of bone metabolism.
Kukuvitis A; Bildiris J; Prapas Y; Tsamis D; Papadimas J; Dimitriadou A; Vlassis G
Gynecol Obstet Invest; 1999; 47(3):194-6. PubMed ID: 10087416
[TBL] [Abstract][Full Text] [Related]
2. Urinary N-telopeptides to monitor bone resorption while on GnRH agonist therapy.
Marshall LA; Cain DF; Dmowski WP; Chesnut CH
Obstet Gynecol; 1996 Mar; 87(3):350-4. PubMed ID: 8598953
[TBL] [Abstract][Full Text] [Related]
3. Reversible bone loss in women treated with GnRH-agonists for endometriosis and uterine leiomyoma.
Waibel-Treber S; Minne HW; Scharla SH; Bremen T; Ziegler R; Leyendecker G
Hum Reprod; 1989 May; 4(4):384-8. PubMed ID: 2526152
[TBL] [Abstract][Full Text] [Related]
4. The effect of gonadotropin-releasing hormone agonist on type I collagen C-telopeptide and N-telopeptide: the predictive value of biochemical markers of bone turnover.
Amama EA; Taga M; Minaguchi H
J Clin Endocrinol Metab; 1998 Feb; 83(2):333-8. PubMed ID: 9467536
[TBL] [Abstract][Full Text] [Related]
5. Excretion of urinary N-telopeptides reflects changes in bone turnover during ovarian suppression and indicates individually variable estradiol threshold for bone loss.
Dmowski WP; Rana N; Pepping P; Cain DF; Clay TH
Fertil Steril; 1996 Dec; 66(6):929-36. PubMed ID: 8941057
[TBL] [Abstract][Full Text] [Related]
6. Clinical usefulness of urinary CrossLaps as a sensitive marker of bone metabolism.
Nakayama H; Yano T; Sagara Y; Ando K; Kasai Y; Taketani Y
Endocr J; 1997 Aug; 44(4):479-84. PubMed ID: 9447279
[TBL] [Abstract][Full Text] [Related]
7. The effect of micronized estradiol on bone turnover and calciotropic hormones in older men receiving hormonal suppression therapy for prostate cancer.
Taxel P; Fall PM; Albertsen PC; Dowsett RD; Trahiotis M; Zimmerman J; Ohannessian C; Raisz LG
J Clin Endocrinol Metab; 2002 Nov; 87(11):4907-13. PubMed ID: 12414849
[TBL] [Abstract][Full Text] [Related]
8. Raloxifene administration in women treated with gonadotropin-releasing hormone agonist for uterine leiomyomas: effects on bone metabolism.
Palomba S; Orio F; Morelli M; Russo T; Pellicano M; Nappi C; Mastrantonio P; Lombardi G; Colao A; Zullo F
J Clin Endocrinol Metab; 2002 Oct; 87(10):4476-81. PubMed ID: 12364422
[TBL] [Abstract][Full Text] [Related]
9. Serum soluble interleukin-6 receptor and biochemical markers of bone metabolism show significant variations during the menstrual cycle.
Gorai I; Taguchi Y; Chaki O; Kikuchi R; Nakayama M; Yang BC; Yokota S; Minaguchi H
J Clin Endocrinol Metab; 1998 Feb; 83(2):326-32. PubMed ID: 9467535
[TBL] [Abstract][Full Text] [Related]
10. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas.
Palomba S; Orio F; Russo T; Falbo A; Cascella T; Doldo P; Nappi C; Lombardi G; Mastrantonio P; Zullo F
Hum Reprod; 2004 Jun; 19(6):1308-14. PubMed ID: 15117890
[TBL] [Abstract][Full Text] [Related]
11. Rapid reduction of uterine leiomyomas with monthly injections of D-Trp6-GnRH.
van Leusden HA; Dogterom AA
Gynecol Endocrinol; 1988 Mar; 2(1):45-51. PubMed ID: 2972173
[TBL] [Abstract][Full Text] [Related]
12. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.
Khan AA; Bilezikian JP; Kung AW; Ahmed MM; Dubois SJ; Ho AY; Schussheim D; Rubin MR; Shaikh AM; Silverberg SJ; Standish TI; Syed Z; Syed ZA
J Clin Endocrinol Metab; 2004 Jul; 89(7):3319-25. PubMed ID: 15240609
[TBL] [Abstract][Full Text] [Related]
13. Effect of chronic renal failure on bone turnover and bone alkaline phosphatase isoforms.
Magnusson P; Sharp CA; Magnusson M; Risteli J; Davie MW; Larsson L
Kidney Int; 2001 Jul; 60(1):257-65. PubMed ID: 11422759
[TBL] [Abstract][Full Text] [Related]
14. Nomegestrol acetate may enhance the skeletal effects of estradiol on biochemical markers of bone turnover in menopausal women after a 12-week treatment period.
Nguyên-Pascal ML; Thomas JL; Bergougnoux L; Garnero P; Drapier-Faure E; Delmas PD
Climacteric; 2005 Jun; 8(2):136-45. PubMed ID: 16096169
[TBL] [Abstract][Full Text] [Related]
15. Cortical remodeling following suppression of endogenous estrogen with analogs of gonadotrophin releasing hormone.
Bell KL; Loveridge N; Lindsay PC; Lunt M; Garrahan N; Compston JE; Reeve J
J Bone Miner Res; 1997 Aug; 12(8):1231-40. PubMed ID: 9258753
[TBL] [Abstract][Full Text] [Related]
16. Serum CA 125 concentrations in women with endometriosis or uterine fibroids treated with gonadotrophin-releasing hormone agonist analogues.
van der Spuy ZM; Wood M; Fieggen G; Hendricks MS
S Afr Med J; 1993 Jul; 83(7):510-3. PubMed ID: 8211493
[TBL] [Abstract][Full Text] [Related]
17. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial.
Marcus R; Holloway L; Wells B; Greendale G; James MK; Wasilauskas C; Kelaghan J
J Bone Miner Res; 1999 Sep; 14(9):1583-95. PubMed ID: 10469288
[TBL] [Abstract][Full Text] [Related]
18. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
Biermasz NR; Hamdy NA; Janssen YJ; Roelfsema F
J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
[TBL] [Abstract][Full Text] [Related]
19. Minodronic acid suppresses gonadotropin-releasing hormone agonist-induced bone remodeling biomarkers: a retrospective pilot study.
Imai A; Matsunami K; Ichigo S; Takagi H
Gynecol Endocrinol; 2016; 32(3):250-2. PubMed ID: 26503621
[TBL] [Abstract][Full Text] [Related]
20. Effects of intranasal 17beta-estradiol on bone turnover and serum insulin-like growth factor I in postmenopausal women.
Garnero P; Tsouderos Y; Marton I; Pelissier C; Varin C; Delmas PD
J Clin Endocrinol Metab; 1999 Jul; 84(7):2390-7. PubMed ID: 10404809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
